A Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Chiauranib for the Treatment of Advanced Solid Tumors and Relapsed/Refractory SCLC
Latest Information Update: 23 Jul 2024
Price :
$35 *
At a glance
- Drugs Ibcasertib (Primary)
- Indications Carcinoma; Colorectal cancer; Liver cancer; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer
- Focus Adverse reactions
- Sponsors Chipscreen Biosciences
- 16 Jul 2024 Planned End Date changed from 1 Apr 2024 to 1 May 2025.
- 16 Jul 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2025.
- 18 Mar 2024 The protocol has been amended addition of pancreatic carcinoma patient in this study.